---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-409833"
form_type: "8-K"
ticker: "GLUE"
cik: "0001826457"
company_name: "Monte Rosa Therapeutics, Inc."
filed_at: "2026-10-01T11:38:04+00:00"
generated_at: "2026-10-12T14:15:09.141599+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Monte Rosa's MRT-8102 cuts hsCRP 85%, Lp(a) 24% in GFORCE-1 Phase 1; three Phase 2 trials planned

## Summary
- GFORCE-1 enrolled 108 obese subjects at elevated CVD risk; MRT-8102 at 5, 20 or 40 mg once daily achieved a median NEK7 reduction of ~80-90% across all three dose levels over 4 weeks of dosing.
- Median biomarker reductions: hsCRP -85%, calprotectin -56%, IL-6 -54%, SAA -51%, S100A12 -46%, fibrinogen -28%; HMGB1 -40% and IL-1β -37% in top-quartile subjects; lipoprotein(a) -24%.
- No serious adverse events reported; TEAEs in 33% of MRT-8102 subjects vs 30% on placebo, no evidence of increased infection risk, and no increases in LDL-C or triglycerides (unlike IL-6(R) blockade).
- Phase 2b GFORCE-2 in stable coronary artery disease + residual inflammation expected H1 2027; GEMINI-1 in gout Q4 2026/Q1 2027 with data H2 2027; GALAXY-1 in hidradenitis suppurativa H1 2027.
- Elevated baseline DAMPs and IL-1β clustered in carriers of NLRP3 risk alleles (~30% of the GFORCE-1 population), supporting a genetically enrichable higher-risk development population.

## SEC filing metadata
- accession: 0001193125-26-409833
- form_type: 8-K
- ticker: GLUE
- cik: 0001826457
- company_name: Monte Rosa Therapeutics, Inc.
- filed_at: 2026-10-01T11:38:04+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1826457/000119312526409833/0001193125-26-409833-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1826457/000119312526409833/glue-20261001.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-409833
- JSON: https://secwatch.observer/filing/0001193125-26-409833.json
- Plain text: https://secwatch.observer/filing/0001193125-26-409833.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.